Challenge of Personalizing therapy for Acute Myeloid Leukemia

Nahla A M Hamed
Additional contact information
Nahla A M Hamed: Professor of Clinical Hematology, Faculty of Medicine, Alexandria University, Egypt

Cancer Therapy & Oncology International Journal, 2020, vol. 16, issue 2, 25-27

Abstract: the aim of precision medicine in AML is to understand the disease biology of each patient to improve patients’ outcomes. This can be done by determining the subgroups of patients who have the greatest response to each therapy and identifying patients who are unlikely to respond to any therapy so drug toxicities can be spared. A number of new agents are studied with the goal of increasing response rates particularly in R/R AML patients or disease that is predicted to be resistant to chemotherapy.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555932.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555932.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:16:y:2020:i:2:p:25-27

DOI: 10.19080/CTOIJ.2020.16.555932

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().